This study is for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread nearby but not to other parts of the body. It's testing a treatment that combines radiation therapy (using high-energy rays to kill cancer cells) with immunotherapy (helping the immune system fight cancer). The medications tested are durvalumab, monalizumab, and oleclumab, which are special proteins called monoclonal antibodies designed to fight cancer cells. This trial aims to see if adding these medications makes the cancer treatment safer and more effective. The trial involves regular check-ups, scans, and blood tests. Participants will receive treatment every 4 weeks for up to 13 cycles and will be followed up for 2 years.
- Length of Study: Active treatment for about 1 year, then follow-up for 2 years.
- Visits Needed: Frequent doctor visits for treatments and check-ups.
- Risks: Possible side effects from medication and radiation.
How understandable was the trial content above?
Hard to understand
Easy to understand